Fig. 3

Lnc-PDZD7 suppresses the chemoresistance of HCC cells. a, Cell viability was examined by MTT assay. The left graph shows the cell viability under different concentrations of 5-Fu treatment in siLnc-PDZD7 or siLnc-scr transfected HepG2 cells. b, A representative image of colony formation after treatment with 5-Fu in siLnc-PDZD7 or siLnc-scr transfected HepG2 cells. c, Tumor formation of siLnc-PDZD7 or siLnc-scr transfected HepG2 cells. Cells were injected subcutaneously into the flanks of nude mice. Then, the mice were injected intraperitoneally with 5-Fu. After four weeks, the tumors in the mice were examined by bioluminescence imaging. Representative images of tumors in each experimental group are shown. d, The tumor growth curves of each group of mice are shown. Six mice were used in each group. The data are shown as the means ± S. D (*P < 0.05). e, Cell viability under different concentrations of sorafenib treatment in Lnc-PDZD7 or Lnc-vec transfected Bel-7402 cells. The data are shown as the means ± S. D (*P < 0.05). f, A representative image of colony formation after treatment with sorafenib in Lnc-PDZD7 or Lnc-vec transfected Bel-7402 cells. g, Tumor formation of Lnc-PDZD7 or Lnc-vec transfected Bel-7402 cells in nude mice. The mice were injected intraperitoneally with sorafenib. H, The tumor growth curves of each group of mice are shown. Six mice were used in each group. The data are shown as the means ± S. D (*P < 0.05)